Pricing Log in Create free account

Immix Biopharma, Inc. (IMMX) vs Nuvectis Pharma, Inc. (NVCT)

Immix Biopharma, Inc. and Nuvectis Pharma, Inc. are both Biotechnology companies. Immix Biopharma, Inc. and Nuvectis Pharma, Inc. are of similar size ($596.9M and $579.8M). Across the 8 metrics below, Immix Biopharma, Inc. leads on 5 and Nuvectis Pharma, Inc. on 3.

Valuation

Metric IMMX NVCT Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 2.23 4.84 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (10.97%) (9.08%) (32.88%)
Free cash flow yield (7.64%) (6.57%) (23.13%)

Profitability

Metric IMMX NVCT Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (34.18%) (66.98%) (51.96%)
Return on assets (31.34%) (57.20%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMMX NVCT Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (17.11%) (18.92%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMMX NVCT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 25.13 9.92 4.97
Net debt to EBITDA 3.39 1.15 1.01

Dividend

Metric IMMX NVCT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMMX NVCT Biotechnology median
Market cap 596.90m 579.76m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack